You are here: Industry Insights > Breast Cancer

News List

Novartis receives FDA approval for Kisqali Femara Co-Pack to treat metastatic breast cancer pharmaceutical-technology
May 11, 2017
Novartis has received the US Food and Drug Administration (FDA) approval for the Kisqali Femara Co-Pack to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+ / HER2-) advanced or metastatic breast cancer in postmenopau
Philips and PathAI team up to improve breast cancer diagnosis using artificial intelligence biospectrumasia
April 25, 2017
Philips has already implemented deep learning in its clinical informatics solutions for radiology
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progressi lilly
April 25, 2017
The Phase 3 study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in patients with HR+, HER2- advanced breast cancer
CASI Pharmaceuticals Reports on Enrollment Status of ENMD-2076 Phase 2 Study in Triple-Negative Brea americanpharmaceuticalreview
April 17, 2017
CASI Pharmaceuticals, Inc. has reported that a decision has been reached to stop further patient enrollment in its Phase 2, open-label study of ENMD-2076...
Report: Southeast Asian Breast Cancer Market to Hit $2.7B by 2022 as Prevalence Rate Rises americanpharmaceuticalreview
April 14, 2017
The Southeast Asian breast cancer market, which covers South Korea, Singapore, Taiwan, China, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, is set to rise from $942.3 million in 2015 to $2.7 billion in 2022.
Improving and extending the lives of patients with advanced breast cancer lilly
April 11, 2017
This article comes from Fatima Cardoso, Chair ABC Global Alliance, on behalf of all members
Ibrance (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2 drugs.com
April 06, 2017
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor...
Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progres lilly
March 21, 2017
Abemaciclib, in combination with fulvestrant, was superior to fulvestrant plus placebo in patients with HR+, HER2- advanced breast cancer
Genomic Health unveils data for the Oncotype DX Breast Cancer test biospectrumasia
March 20, 2017
This test uses genomic analysis techniques to uncover the unique footprint of each patient's tumour
Novartis' Kisqali garners FDA approval as first-line breast cancer treatment firstwordpharma
March 15, 2017
The FDA approved Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor positive, HER2-negative advanced or metastatic breast cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page